Roche study data highlights further benefits of lung cancer drug Alecensa

Roche has reported data from a phase III clinical trial that offers further evidence of the promising nature of its new lung cancer therapy Alecensa.

The study, ALUR, was able to meet its primary endpoint after demonstrating that Alecensa significantly improved progression-free survival in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who had progressed following treatment with one prior line of platinum-based chemotherapy and crizotinib.

In doing so, the therapy showed a superior performance than chemotherapy, suggesting it could be a valuable new therapeutic option for this patient group.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "The results of this trial will support our access discussions with global health authorities as we seek to bring Alecensa to patients faster."

The company has also recently reported data from another phase III study called ALEX, which showed that Alecensa, when used as a first-line treatment, can significantly improve progression-free survival rates in people with ALK-positive advanced NSCLC compared to an established therapy.

Around 75,000 people globally are diagnosed with ALK-positive NSCLC every year, affecting younger people and women most commonly.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.